+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Imfinzi (durvalumab; AstraZeneca) Drug Overview 2019

  • ID: 4462230
  • Drug Pipelines
  • September 2019
  • Region: Global
  • 57 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Imfinzi (durvalumab; AstraZeneca) is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling pathways that affect T-cell activation, proliferation, and survival, and can induce apoptosis of tumor-specific T cells.

By inhibiting the PD-1/PD-L1 interaction, Imfinzi reduces the ability of the tumor to evade immune system targeting and enables the activation of T cells and the adaptive immune system
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
  • Drug Overview
  • Product Profiles
  • Imfinzi : Hepatocellular carcinoma (HCC)
  • Imfinzi : Non-small cell lung cancer (NSCLC)
  • Imfinzi : Head and neck cancer
  • Imfinzi : Bladder cancer
LIST OF FIGURES
Figure 1: The author's drug assessment summary of Imfinzi for HCC
Figure 1: The author's assessment summary of key marketed and pipeline drugs for HCC
Figure 2: HCC total market value across the US, Japan, and five major EU markets, by country, 2018−27
Figure 4: HCC sales in Japan, 2018–27
Figure 5: HCC sales in the five major EU markets, by country, 2018–27
Figure 6: The author's drug assessment summary for Imfinzi in non-small cell lung cancer
Figure 7: Imfinzi sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 8: Imfinzi for head and neck cancer – SWOT analysis
Figure 6: Price sources and calculations, by country
Figure 7: The author's drug assessment summary of Cabometyx for HCC
Figure 9: Cabometyx sales for HCC across the US, Japan, and five major EU markets, by country, 2018–27
Figure 12: The author's drug assessment summary for Imfinzi in urothelial bladder cancer

LIST OF TABLES
Table 1: Imfinzi drug profile
Table 2: Trials of Imfinzi for HCC
Table 3: Imfinzi for HCC – SWOT analysis
Table 4: Imfinzi drug profile
Table 5: Imfinzi pivotal trial data in non-small cell lung cancer
Table 6: Imfinzi late-phase trial data in non-small cell lung cancer
Table 7: Imfinzi ongoing late-phase clinical trials in non-small cell lung cancer
Table 8: Imfinzi sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 9: Imfinzi patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 10: Imfinzi drug profile
Table 11: Imfinzi Phase III trials in head and neck cancer
Table 12: Imfinzi early-phase data in head and neck cancer
Table 13: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 14: Imfinzi patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
Table 15: Imfinzi drug profile
Table 16: Imfinzi pivotal trial data in urothelial bladder cancer
Table 17: Imfinzi ongoing late-phase trials in urothelial bladder cancer
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll